A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)

NCT01305499 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Entinostat days 3, 10
DRUG: 5AC
DRUG: Entinostat days 10,17

Sponsor

Hetty Carraway